HK1202056A1 - Formulations of ()-2-[1-(3-ethoxy-4-methoxy-phenyl)-2- methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione ()-2-[1-(3--4--)-2--]-4- -13- - Google Patents
Formulations of ()-2-[1-(3-ethoxy-4-methoxy-phenyl)-2- methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione ()-2-[1-(3--4--)-2--]-4- -13-Info
- Publication number
- HK1202056A1 HK1202056A1 HK15102544.0A HK15102544A HK1202056A1 HK 1202056 A1 HK1202056 A1 HK 1202056A1 HK 15102544 A HK15102544 A HK 15102544A HK 1202056 A1 HK1202056 A1 HK 1202056A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- aminoisoindoline
- methanesulfonyl
- dione
- ethoxy
- acetyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161580626P | 2011-12-27 | 2011-12-27 | |
PCT/US2012/071623 WO2013101810A1 (en) | 2011-12-27 | 2012-12-26 | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202056A1 true HK1202056A1 (en) | 2015-09-18 |
Family
ID=47459206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102544.0A HK1202056A1 (en) | 2011-12-27 | 2015-03-12 | Formulations of ()-2-[1-(3-ethoxy-4-methoxy-phenyl)-2- methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione ()-2-[1-(3--4--)-2--]-4- -13- |
Country Status (33)
Country | Link |
---|---|
US (2) | US20130164376A1 (sl) |
EP (2) | EP3756650A1 (sl) |
JP (1) | JP6161629B2 (sl) |
KR (3) | KR102035362B1 (sl) |
CN (1) | CN104136003A (sl) |
AU (1) | AU2012362562B2 (sl) |
BR (1) | BR112014015923B1 (sl) |
CA (1) | CA2861594A1 (sl) |
CL (1) | CL2014001726A1 (sl) |
CO (1) | CO7000777A2 (sl) |
CR (1) | CR20140314A (sl) |
CY (1) | CY1123174T1 (sl) |
DK (1) | DK2797581T3 (sl) |
EA (1) | EA027801B1 (sl) |
EC (1) | ECSP14007965A (sl) |
ES (1) | ES2799448T3 (sl) |
HK (1) | HK1202056A1 (sl) |
HR (1) | HRP20200825T1 (sl) |
HU (1) | HUE050327T2 (sl) |
IL (1) | IL233296B (sl) |
LT (1) | LT2797581T (sl) |
MX (2) | MX2014007878A (sl) |
NI (1) | NI201400068A (sl) |
PE (1) | PE20142318A1 (sl) |
PH (1) | PH12014501495B1 (sl) |
PL (1) | PL2797581T3 (sl) |
PT (1) | PT2797581T (sl) |
RS (1) | RS60415B1 (sl) |
SG (2) | SG10201605251VA (sl) |
SI (1) | SI2797581T1 (sl) |
UA (1) | UA113750C2 (sl) |
WO (1) | WO2013101810A1 (sl) |
ZA (1) | ZA201404629B (sl) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2848493A1 (en) | 2011-09-14 | 2013-03-21 | Celgene Corporation | Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
PL2797581T3 (pl) | 2011-12-27 | 2020-10-05 | Amgen (Europe) GmbH | Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu |
EP3143004B1 (en) | 2014-05-11 | 2020-09-02 | Mapi Pharma Limited | Amorphous form of apremilast |
WO2016016824A1 (en) | 2014-07-29 | 2016-02-04 | Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca | Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis |
TWI795344B (zh) * | 2015-06-30 | 2023-03-11 | 美商建南德克公司 | 含藥物之立即釋放錠劑及形成該錠劑的方法 |
CZ20165A3 (cs) * | 2016-01-06 | 2017-07-19 | Zentiva, K.S. | Způsoby přípravy amorfního apremilastu |
BR112018076114A2 (pt) | 2016-06-15 | 2019-03-26 | Torrent Pharmaceuticals Limited | composições tópicas de apremilast |
EP3962475A1 (en) * | 2019-04-30 | 2022-03-09 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
ES2823927B2 (es) * | 2019-11-07 | 2022-01-18 | Beijing Enbiwo Biological Tech Co Ltd | Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales |
KR20220047105A (ko) | 2020-10-08 | 2022-04-15 | 주식회사 엔비피헬스케어 | 아프레밀라스트를 함유하는 약학 조성물 |
CN112245403B (zh) * | 2020-10-23 | 2022-04-22 | 杭州朱养心药业有限公司 | 磷酸二酯酶-4抑制剂及其口服固体组合物 |
EP4183389A1 (en) | 2021-11-18 | 2023-05-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apremilast |
WO2023118043A1 (en) | 2021-12-22 | 2023-06-29 | Biohorm, S.L. | Pharmaceutical compositions of apremilast |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
ES2529190T3 (es) | 1996-07-24 | 2015-02-17 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6448323B1 (en) | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
WO2003041326A2 (en) | 2001-11-09 | 2003-05-15 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
EP1694328A4 (en) | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
ZA200607799B (en) | 2004-03-22 | 2008-06-25 | Celgene Corp | Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of skin diseases or disorders |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
WO2005105088A2 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
CN101098694A (zh) | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
US20060122228A1 (en) | 2004-11-23 | 2006-06-08 | Zeldis Jerome B | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
EP1924250B1 (en) | 2004-12-01 | 2017-01-04 | Celgene Corporation | Methods and compositions comprising immunomodulatory compounds for use for the treatment of immunodeficiency disorders |
JP2008530145A (ja) * | 2005-02-15 | 2008-08-07 | ワイス | 経口投与可能なcci−779製剤 |
WO2006097344A1 (en) * | 2005-03-17 | 2006-09-21 | Synthon B.V. | Pharmaceutical tablets of crystalline type ii aripiprazole |
WO2006111980A2 (en) | 2005-04-20 | 2006-10-26 | Ideal Cures Pvt. Ltd. | Pva based film coating and film coating compositions |
ATE499112T1 (de) | 2005-09-01 | 2011-03-15 | Celgene Corp | Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
DE102008047910A1 (de) * | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
PE20120580A1 (es) | 2009-02-10 | 2012-05-23 | Celgene Corp | Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis |
US8871264B2 (en) | 2009-11-13 | 2014-10-28 | Astrazeneca Ab | Immediate release tablet formulations |
CN103442698B (zh) * | 2010-12-16 | 2016-10-05 | 细胞基因公司 | 难溶性药物的控释口服剂量形式及其用途 |
PL2797581T3 (pl) | 2011-12-27 | 2020-10-05 | Amgen (Europe) GmbH | Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu |
-
2012
- 2012-12-26 PL PL12808662T patent/PL2797581T3/pl unknown
- 2012-12-26 BR BR112014015923-8A patent/BR112014015923B1/pt active IP Right Grant
- 2012-12-26 LT LTEP12808662.6T patent/LT2797581T/lt unknown
- 2012-12-26 SG SG10201605251VA patent/SG10201605251VA/en unknown
- 2012-12-26 KR KR1020147020953A patent/KR102035362B1/ko active IP Right Grant
- 2012-12-26 MX MX2014007878A patent/MX2014007878A/es active IP Right Grant
- 2012-12-26 UA UAA201408510A patent/UA113750C2/uk unknown
- 2012-12-26 EP EP20172615.5A patent/EP3756650A1/en active Pending
- 2012-12-26 RS RS20200715A patent/RS60415B1/sr unknown
- 2012-12-26 PT PT128086626T patent/PT2797581T/pt unknown
- 2012-12-26 SI SI201231796T patent/SI2797581T1/sl unknown
- 2012-12-26 CN CN201280070694.5A patent/CN104136003A/zh active Pending
- 2012-12-26 US US13/727,366 patent/US20130164376A1/en not_active Abandoned
- 2012-12-26 JP JP2014550424A patent/JP6161629B2/ja active Active
- 2012-12-26 CA CA2861594A patent/CA2861594A1/en active Pending
- 2012-12-26 AU AU2012362562A patent/AU2012362562B2/en active Active
- 2012-12-26 HU HUE12808662A patent/HUE050327T2/hu unknown
- 2012-12-26 KR KR1020197030218A patent/KR102232154B1/ko active IP Right Grant
- 2012-12-26 DK DK12808662.6T patent/DK2797581T3/da active
- 2012-12-26 SG SG11201403564YA patent/SG11201403564YA/en unknown
- 2012-12-26 EA EA201491292A patent/EA027801B1/ru not_active IP Right Cessation
- 2012-12-26 EP EP12808662.6A patent/EP2797581B1/en not_active Revoked
- 2012-12-26 ES ES12808662T patent/ES2799448T3/es active Active
- 2012-12-26 WO PCT/US2012/071623 patent/WO2013101810A1/en active Application Filing
- 2012-12-26 KR KR1020217008170A patent/KR20210033073A/ko not_active IP Right Cessation
- 2012-12-26 PE PE2014001038A patent/PE20142318A1/es not_active Application Discontinuation
-
2014
- 2014-06-22 IL IL233296A patent/IL233296B/en active IP Right Grant
- 2014-06-24 ZA ZA2014/04629A patent/ZA201404629B/en unknown
- 2014-06-26 CL CL2014001726A patent/CL2014001726A1/es unknown
- 2014-06-26 NI NI201400068A patent/NI201400068A/es unknown
- 2014-06-26 MX MX2020005145A patent/MX2020005145A/es unknown
- 2014-06-27 PH PH12014501495A patent/PH12014501495B1/en unknown
- 2014-06-27 CR CR20140314A patent/CR20140314A/es unknown
- 2014-07-03 EC ECIEPI20147965A patent/ECSP14007965A/es unknown
- 2014-07-09 CO CO14147911A patent/CO7000777A2/es unknown
-
2015
- 2015-03-12 HK HK15102544.0A patent/HK1202056A1/xx unknown
-
2020
- 2020-05-14 US US16/874,424 patent/US20210093573A1/en active Pending
- 2020-05-21 HR HRP20200825TT patent/HRP20200825T1/hr unknown
- 2020-06-25 CY CY20201100590T patent/CY1123174T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1202056A1 (en) | Formulations of ()-2-[1-(3-ethoxy-4-methoxy-phenyl)-2- methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione ()-2-[1-(3--4--)-2--]-4- -13- | |
IL273050A (en) | Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine | |
ZA201403969B (en) | 2-(substituted-phenyl)=cyclopentane-1,3-dione compounds, and derivatives thereof | |
HK1199255A1 (en) | Indazole compounds, compositions and methods of use | |
IL230836A (en) | Multi-part disinfectant system | |
EP2720631A4 (en) | SURGICAL ALIGNMENT USING REFERENCES | |
IL230662A0 (en) | Indazole-type substances, preparations containing these substances and their uses | |
ZA201701083B (en) | Decitabine derivative formulations | |
EP2667868A4 (en) | Benda MUSTIN FORMULATIONS | |
SI2753311T1 (sl) | Formulacije antioksidanta | |
HK1213785A1 (zh) | 血管緊張素的口服製劑 | |
GB201110278D0 (en) | Formulations | |
TH1401003680A (th) | สูตรผสมของ (+)-2-[1-(3-อีธอกซิ-4-เมธอกซิ-ฟีนิล)-2-มีเธนซัลโฟนิล-เอธิล]-4- อะซิติลอะมิโนไอโซอินโดไลน์-1,3-ไดโอน | |
GB201111578D0 (en) | Pharmeutical formulations | |
GB201111013D0 (en) | Formulations | |
GB201107627D0 (en) | Formulations | |
GB201107626D0 (en) | Formulations | |
GB201105410D0 (en) | Formulations | |
GB201105360D0 (en) | Formulations | |
GB201104049D0 (en) | Formulations | |
GB201104048D0 (en) | Formulations | |
GB201102795D0 (en) | Formulations | |
GB201109725D0 (en) | Push-pull outlet | |
GB201118385D0 (en) | Alternative removable outlet | |
AU2011900565A0 (en) | Horseshoe |